Literature DB >> 26667973

Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications.

Eric Van Cutsem1, Michel Ducreux2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26667973     DOI: 10.1038/nrclinonc.2015.217

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

1.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

2.  Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Authors:  Josep Tabernero; Heinz-Josef Lenz; Salvatore Siena; Alberto Sobrero; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Takayuki Yoshino; Richard M Goldberg; Daniel J Sargent; Andrea Wagner; Dirk Laurent; Michael Teufel; Michael Jeffers; Axel Grothey; Eric Van Cutsem
Journal:  Lancet Oncol       Date:  2015-07-13       Impact factor: 41.316

3.  Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Authors:  Rodrigo Dienstmann; Amita Patnaik; Rocio Garcia-Carbonero; Andrés Cervantes; Marta Benavent; Susana Roselló; Bastiaan B J Tops; Rachel S van der Post; Guillem Argilés; Niels J Ø Skartved; Ulla H Hansen; Rikke Hald; Mikkel W Pedersen; Michael Kragh; Ivan D Horak; Stephan Braun; Eric Van Cutsem; Anthony W Tolcher; Josep Tabernero
Journal:  Cancer Discov       Date:  2015-05-11       Impact factor: 39.397

4.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

5.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

6.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Authors:  Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing
Journal:  Lancet Oncol       Date:  2014-07-31       Impact factor: 41.316

7.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

8.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

9.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

10.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  12 in total

1.  Upregulation of ROCK2 in gastric cancer cell promotes tumor cell proliferation, metastasis and invasion.

Authors:  Manhua Li; Jing Ke; Qiuhong Wang; Hongyan Qian; Lei Yang; Xunlei Zhang; Jinzhang Xiao; Haifang Ding; Xiaohang Shan; Qingqing Liu; Ying Xiao; Bojun Bao; Hua Huang
Journal:  Clin Exp Med       Date:  2016-12-05       Impact factor: 3.984

Review 2.  Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance.

Authors:  Xiaolin Wang; Jiahui Zhang; Guozhen Cao; Jinghan Hua; Ge Shan; Wenchu Lin
Journal:  J Exp Clin Cancer Res       Date:  2022-07-11

3.  Correlation of Gli1 and HER2 expression in gastric cancer: Identification of novel target.

Authors:  Xinyu Shao; Xiaoyi Kuai; Zhi Pang; Liping Zhang; Longyun Wu; Lijuan Xu; Chunli Zhou
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

4.  Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.

Authors:  Alessia Mira; Virginia Morello; Maria Virtudes Céspedes; Timothy Perera; Paolo M Comoglio; Ramon Mangues; Paolo Michieli
Journal:  Oncotarget       Date:  2017-06-13

5.  Long non-coding RNA CCDC144NL-AS1 sponges miR-143-3p and regulates MAP3K7 by acting as a competing endogenous RNA in gastric cancer.

Authors:  Hao Fan; Yugang Ge; Xiang Ma; Zengliang Li; Liang Shi; Linling Lin; Jian Xiao; Wangwang Chen; Peidong Ni; Li Yang; Zekuan Xu
Journal:  Cell Death Dis       Date:  2020-07-09       Impact factor: 8.469

6.  Tumour suppressive long non-coding RNA AFDN-DT inhibits gastric cancer invasion via transcriptional regulation.

Authors:  Yuexing Lai; Ping Xu; Jing Wang; Kai Xu; Lin Wang; Yuchen Meng
Journal:  J Cell Mol Med       Date:  2020-01-24       Impact factor: 5.310

7.  STRA6 exerts oncogenic role in gastric tumorigenesis by acting as a crucial target of miR-873.

Authors:  Linling Lin; Jian Xiao; Liang Shi; Wangwang Chen; Yugang Ge; Mingkun Jiang; Zengliang Li; Hao Fan; Li Yang; Zekuan Xu
Journal:  J Exp Clin Cancer Res       Date:  2019-11-06

8.  Downregulated SIRT6 and upregulated NMNAT2 are associated with the presence, depth and stage of colorectal cancer.

Authors:  Jia Qi; Chunhui Cui; Quanwen Deng; Lifeng Wang; Rihong Chen; Duanyang Zhai; Lang Xie; Jinlong Yu
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

9.  MEF2A-mediated lncRNA HCP5 Inhibits Gastric Cancer Progression via MiR-106b-5p/p21 Axis.

Authors:  Weiwei Chen; Kundong Zhang; Yuhan Yang; Zengya Guo; Xiaofeng Wang; Buwei Teng; Qian Zhao; Chen Huang; Zhengjun Qiu
Journal:  Int J Biol Sci       Date:  2021-01-16       Impact factor: 6.580

10.  Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate Hepatitis A Virus Cellular Receptor 1 expression.

Authors:  Yurong Chen; Renchao Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.